nach oben

Current Oncology Reports

Erschienen in:

01.01.2020 | Palliative Medicine (A Jatoi, Section Editor)

Nausea and Vomiting: a Palliative Care Imperative

verfasst von: Rita J. Wickham

Erschienen in: Current Oncology Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review was undertaken to survey recent literature for research reports and comprehensive clinical reviews addressing the pharmacologic management of nausea and vomiting (N&V) in advanced cancer. The goal was to integrate findings in a comprehensive article that incorporates palliative care concepts into antiemetic treatment.

Recent Findings

There are few published studies of N&V in advanced cancer; such research may be limited by the multicausal nature of N&V and participant burden to patients with life-limiting disease. Most articles are written by oncologists who also specialize in palliative care, and those addressing adverse effects of drugs used as antiemetics are found in other literature. Articles addressing more novel therapies, like cannabinoids and medical marijuana, are uncommon in the oncology literature.

Summary

N&V in patients with progressive or advanced cancer is often multicausal. Nausea is more common and persistent, and even mild nausea is bothersome and may cause anxiety or depression. The mechanisms of nausea and vomiting overlap, but different neural pathways constitute the final pathway for each—the brainstem for vomiting and higher brain regions for nausea. Common causes of N&V in advanced cancer include constipation, opioids, and malignant bowel obstruction. About 40% have undetermined causes and may be exacerbated by impaired gastric emptying, chemical imbalances, or other factors. Several drugs that have antiemetic effects and act at different receptors are used to palliate N&V. There is a paucity of research that supports palliative antiemetic choices, and other research is needed to define potential therapeutic strategies that capitalize on differences between nausea and vomiting.

Hawley PH. The bow tie model of 21st century palliative care. J Pain Symptom Manag. 2014;47(1):e2–5. https://doi.org/10.1016/j.jpainsymman.2013.10.009.CrossRef

Li B, Mah K, Swami N, et al. Symptom assessment in patients with advanced cancer: are the most severe symptoms the most bothersome? J Palliat Med. 2019. https://doi.org/10.1089/jpm.2018.0622.CrossRef

• Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23:806–13. https://doi.org/10.1093/cercor/bhs073. Functional MRI study investigated brain regions involved in temporal evolution of nausea; greater nausea intensity was associated sustained activation in a broader network of interoceptive, limbic, somatosensory, and cognitive processing areas in the human brain. CrossRefPubMed

Balaban CD, Yates BJ. What is nausea? A historical analysis of changing views. Auton Neurosci. 2017;202:5–17. https://doi.org/10.1016/j.autneu.2016.07.003.CrossRefPubMed

•• Wickham RJ. Revisiting the physiology of nausea and vomiting—challenging the paradigm. Support Care Cancer. Online first: 06 August 2019. https://doi.org/10.1007/s00520. Current, in-depth review of differing physiological mechanisms, neural pathways, transmitters and receptors for vomiting and for nausea; new proposed paradigm for nausea and for vomiting.

Gogolla N. The insular cortex. Curr Biol. 2017;27:R573–91. https://doi.org/10.1016/j.cub.2017.05.010.CrossRef

Craig AD. How do you feel — now? The anterior insula and human awareness. Nat Rev Neurosci. 2009;10:59–70. https://doi.org/10.1038/nrn2555.CrossRefPubMed

Harder S, Herrstedt J, Isaksen J, et al. The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. Support Care Cancer. 2019. https://doi.org/10.1007/s00520-018-4623-1.CrossRef

Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9(1):98–112. https://doi.org/10.1177/1756283X15618131.CrossRef

10.

Sande TA, Laird BJ, Fallon MT. The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med. 2019;22(1):90–7. https://doi.org/10.1089/jpm.2018.0260.CrossRefPubMed

11.

Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59. https://doi.org/10.2147/CIA.S13109.CrossRefPubMedPubMedCentral

12.

Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333–40. https://doi.org/10.1007/s00520-016-3371-3.CrossRefPubMed

13.

Collis E, Mather H. Nausea and vomiting in palliative care. BMJ. 2015;351:h6249. https://doi.org/10.1136/bmj.h6249.CrossRefPubMed

14.

Ferguson HJM, Ferguson CI, Speakman J, Ismail T. Management of intestinal obstruction in advanced malignancy. Ann Med Surg (Lond). 2015;4(3):264–70. https://doi.org/10.1016/j.amsu.2015.07.018.CrossRef

15.

• Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manag. 2014;8(1):75–91. https://doi.org/10.1016/j.jpainsymman.2013.08.022. French Health Authority (HAS) evidence-based clinical guidelines for the diagnosis and management of bowel obstruction. CrossRef

16.

Soriano A, Davis MP. Malignant bowel obstruction: individualized treatment near the end of life. Cleve Clin J Med. 2011;78(3):197–206. https://doi.org/10.3949/ccjm.78a.10052.CrossRefPubMed

17.

Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW. Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manag. 2016;52(6):901–19. https://doi.org/10.1016/j.jpainsymman.2016.05.032.CrossRef

18.

Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015;13:50. https://doi.org/10.1186/s12957-015-0455-3.CrossRefPubMedPubMedCentral

19.

Harris DG. Nausea and vomiting in advanced cancer. Br Med Bull. 2010;96(1):175–85. https://doi.org/10.1093/bmb/ldq031.CrossRefPubMed

20.

To THM, Agar M, Yates P, Currow DC. Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors. J Palliat Med. 2014;17(9):1032–6. https://doi.org/10.1089/jpm.2013.0610.CrossRef

21.

Valkova M, Stamenov B, Peychinska D, et al. Metoclopramide-induced extrapyramidal signs and symptoms – brief review of literature and case report. J IMAB. 2014;20(6):539–41. https://doi.org/10.5272/jimab.2014206.539.CrossRef

22.

Gordon P, LeGrand SB, Walsh D. Nausea and vomiting in advanced cancer. Eur J Pharmacol. 2014;722:187–91. https://doi.org/10.1016/j.ejphar.2013.10.010.CrossRefPubMed

23.

Gupta N, Puri S, Kumar V, Garg R, Bharati SJ, Mishra S, et al. Olanzapine in the treatment of refractory nausea and vomiting in palliative care settings. Indian J Palliat Care. 2018;24(3):372–4. https://doi.org/10.4103/IJPC.IJPC_30_18.CrossRefPubMedPubMedCentral

24.

Lewis K, O’Day CS. Dystonic reactions. In: StatPearls (nternet). Updated3/23/ 2019. Treasure Island: StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531466/?report=classic. Accessed 11 Sept 2019.

25.

Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am. 2016;39(3):391–411. https://doi.org/10.1016/j.psc.2016.04.003.CrossRefPubMed

26.

Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Physician. 2017;46(5):296–8.PubMed

27.

Poyurovsky M, Weizman A. Treatment of antipsychotic-related akathisia revisited. The role of serotonin 2A receptor antagonists. J Clin Psychopharmacol. 2015;35(6):711–4. https://doi.org/10.1097/JCP.0000000000000412.CrossRefPubMed

28.

Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004;18:195–201. https://doi.org/10.1191/0269216304pm881oa.CrossRefPubMed

29.

Prommer E. Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat Care. 2012;29(4):295–301. https://doi.org/10.1177/1049909111423094.CrossRefPubMed

30.

Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients (review). Cochrane Database Syst Rev. 2015;(11). https://doi.org/10.1002/14651858.CD006271.pub3.

31.

Digges M, Hussein A, Wilcock A, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting. J Palliat Med. 2018;21(1):37–43. https://doi.org/10.1089/jpm.2017.0159.CrossRefPubMed

32.

MacKintosh D. Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series. J Palliat Med. 2016;19(1):87–90. https://doi.org/10.1089/jpm.2015.0224.CrossRefPubMed

33.

• Credible Meds. 2019. Available at https://crediblemeds.org/healthcare-providers/. This site, which is frequently updated, lists evidence-based prescription and recreational (cocaine) drugs having the potential to increase the QT interval and induce Torsades de pointes.

34.

Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet J Rare Dis. 2008;3:18. https://doi.org/10.1186/1750-1172-3-18.CrossRefPubMedPubMedCentral

35.

Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care. 2007l;16(4):351–4. https://doi.org/10.1111/j.1365-2354.2006.00760.x.CrossRef

36.

Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96. https://doi.org/10.1016/0893-133X(94)00129-N.CrossRefPubMed

37.

Passik SD, Lundberg J, Kirsh KL. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23(6):526–32. https://doi.org/10.1016/S0885-3924(02)00391.CrossRef

38.

Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44(4):604–7. https://doi.org/10.1016/j.jpainsymman.2011.10.023.CrossRef

39.

Raji MA. Management of chemotherapy-induced side-effects. Lancet Oncol. 2005;6(6):357. https://doi.org/10.1016/S1470-2045(05)70182-0.CrossRefPubMed

40.

Allen ND, Leung JG, Betcher HK, Borreggine KL, Hosker DK, Minton BA, et al. Mirtazapine for symptomatic relief on a psychiatric consultation service: a case series. Psychosomatics. 2016;57(4):409–13. https://doi.org/10.1016/j.psym.2016.02.012.CrossRefPubMed

41.

Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64. https://doi.org/10.1111/j.1527-3458.2001.tb00198.x.CrossRefPubMedPubMedCentral

42.

Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017;11:1035–41. https://doi.org/10.2147/DDDT.S125743.CrossRefPubMedPubMedCentral

43.

Kumar N, Barai S, Gambhir S, Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J Palliat Care. 2017;23(3):335–7. https://doi.org/10.4103/IJPC.IJPC_17_17.CrossRefPubMedPubMedCentral

44.

Jaward LR, O’Neil TA, Marks A, Smith MA. Differences adverse effect profiles of corticosteroids in palliative care patients. Am J Hosp Palliat Med. 2019;36(2):158–68. https://doi.org/10.1177/1049909118797283.CrossRef

45.

Vayne-Bossert P, Haywood A, Good P, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery). Cochrane Database Syst Rev. 2017;(7). https://doi.org/10.1002/14651858.CD012002.pub2.

46.

Hatano Y, Matsuoka H, Lam L, Currow DC. Side effects of corticosteroids in patients with advanced cancer: a systematic review. Support Care Cancer. 2018;26:3979–83. https://doi.org/10.1007/s00520-018-4339-2.CrossRefPubMed

47.

Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care. 2013;12:2. https://doi.org/10.1186/1472-684X-12-2.CrossRefPubMedPubMedCentral

48.

Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979;28:2161–5. https://doi.org/10.1016/0006-2952(79)90198-9.CrossRefPubMed

49.

Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–40.CrossRef

50.

Bor S, Demir M, Ozdemi O, Yuksel K. A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide. United European Gastroenterol J. 2018v;6(9):1331–46. https://doi.org/10.1177/2050640618799153.CrossRefPubMedPubMedCentral

51.

Field J, Wasilewski M, Bhuta R, et al. Effect of chronic domperidone use on QT interval: a large single center study. J Clin Gastroenterol. 2019. https://doi.org/10.1097/MCG.0000000000001183.CrossRef

52.

Ortiz A, Cooper CJ, Alvarez A, Gomez Y, Sarosiek I, McCallum R. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349:421–4. https://doi.org/10.1097/MAJ.0000000000000439.CrossRefPubMedPubMedCentral

53.

Gonzalez-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manag. 1997;14(5):311–4. https://doi.org/10.1016/S0885-3924(97)00229-7.CrossRef

54.

Zutt M, Hänßle H, Emmert S, et al. Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen (Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases). Hautarzt. 2006;57(5):423–7. https://doi.org/10.1007/s00105-005-1063.CrossRefPubMed

55.

Hernandez SL, Sheyner I, Stover KT, Stewart JT. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Care. 2015;32(1):5–7. https://doi.org/10.1177/1049909113504240.CrossRefPubMed

56.

Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci. 2006;27(3):134–40. https://doi.org/10.1016/j.tips.2006.01.010.CrossRefPubMed

57.

Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95:311–27. https://doi.org/10.1139/cjpp-2016-0346.CrossRefPubMed

58.

•• National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. https://doi.org/10.17226/24625. A comprehensive, in-depth review of existing evidence and summary recommendations regarding health effects of cannabis and cannabis-derived products, as well as potential therapeutic uses. This work was implemented to help advance research and inform public health decisions. CrossRef

59.

• Schleider LB-L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018;49:37–43. https://doi.org/10.1016/j.ejim.2018.01.023. Analysis of routinely collected data regarding the benefits and burdens of medical marijuana, prescribed to almost 3000 cancer patients with symptomatic disease who were followed over 2 years. This article also describes the processes of physician prescription and nurse selection (with patient) of particular cannabis strains, dose escalation, and patient and family teaching. CrossRef

60.

Abrams DI. Integrating cannabis into clinical cancer care. Curr Oncol. 2016;23(2):S8–S14. https://doi.org/10.3747/co.23.3099.CrossRefPubMedPubMedCentral

Titel: Nausea and Vomiting: a Palliative Care Imperative
verfasst von: Rita J. Wickham
Publikationsdatum: 01.01.2020
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 1/2020
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-020-0871-6

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Nausea and Vomiting: a Palliative Care Imperative

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma

Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation

Low-grade Serous Tumors: Are We Making Progress?

The Emerging Role of Local Therapy in Metastatic Prostate Cancer

Current Understanding of Urachal Adenocarcinoma and Management Strategy

Genetic Testing in Prostate Cancer

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie